Health Systems Stop Buying Software. They're Building Proprietary Platforms Instead.

Two academic medical centers just made a bet that could reshape how hospitals approach clinical decision support—and how health tech vendors compete for their business. NYU Langone Health and Dana-Farber Cancer Institute are commercializing an internally developed oncology decision support tool, joining a small but growing cohort of health systems that have chosen to build proprietary software rather than license existing platforms. The move signals a fundamental shift in how leading institutions view their technology infrastructure: not as a cost center requiring vendor partnerships, but as a potential revenue stream and competitive moat.

The decision to build rather than buy in oncology is particularly telling. Cancer care represents one of the fastest-growing segments of healthcare spending, and clinical decision support tools in this space directly impact treatment selection, drug sequencing, and patient outcomes. With the FDA approving increasingly complex therapies—including Tudriqev, a genetically modified oncolytic viral therapy for treatment-resistant advanced melanoma approved in August 2026—oncologists face escalating pressure to navigate expanding treatment algorithms . Decision support tools that help clinicians match patients to appropriate therapies at the right time are no longer nice-to-have; they determine whether institutions can deliver cutting-edge care efficiently.

For healthcare marketers, this trend creates both opportunity and disruption. Health systems that succeed in commercializing homegrown software gain not just operational advantages, but powerful positioning tools: proof of clinical innovation, new revenue channels, and differentiation in competitive markets.

The strategic calculus behind build-versus-buy decisions extends far beyond IT departments. When a health system like NYU Langone or Dana-Farber commits resources to developing proprietary clinical software, they are making a statement about institutional priorities, competitive strategy, and long-term market positioning. These decisions carry direct implications for how these organizations market themselves to patients, recruit physicians, and negotiate with payers.

The Economics of Building Proprietary Clinical Tools

Health systems typically purchase enterprise software because vendor solutions offer speed, support infrastructure, and shared development costs across multiple clients. Building from scratch requires significant capital investment, specialized technical talent, and ongoing maintenance costs that can exceed initial development budgets by multiples.

Yet for institutions with sufficient scale and technical sophistication, the economics can favor internal development. Proprietary tools can be customized to exact workflow specifications, integrated seamlessly with existing EHR systems, and modified rapidly as clinical protocols evolve. More significantly, successful tools become intellectual property that can be licensed to other health systems, creating new revenue streams.

The oncology space proves particularly attractive for this approach. Treatment protocols in cancer care change rapidly as new therapies receive FDA approval. Tudriqev's August 2026 approval for advanced melanoma patients who progressed on anti-PD-1 therapy illustrates this dynamic perfectly—the approval created an immediate need for decision support tools that could identify appropriate candidates, sequence the viral therapy with nivolumab correctly, and track response patterns . Off-the-shelf software often lags six to eighteen months behind new drug approvals, leaving a gap that in-house development teams can fill in real time.

Health systems that build these tools gain operational advantages: their oncologists work with software designed specifically for their patient populations and institutional protocols. But they also gain marketing advantages that cannot be purchased from vendors. A proprietary decision support tool becomes evidence of clinical innovation, a recruiting tool for top oncology talent, and a differentiator when competing for complex cancer cases in regional markets.

What This Means for Healthcare Marketing Strategy

The NYU Langone and Dana-Farber commercialization effort creates a template that other health systems will study—and some will replicate. For healthcare marketers, this shift from buyer to builder changes the competitive landscape in three specific ways.

First, proprietary clinical software becomes a content engine. Health systems can now market not just outcomes, but the technology infrastructure that enables those outcomes. Patient acquisition campaigns can highlight decision support tools as tangible evidence of clinical sophistication. Physician recruitment materials can emphasize access to proprietary technology as a practice advantage. Media relations strategies can position institutional leaders as health tech innovators, not just clinicians.

Second, the commercialization component creates validation opportunities that purchased software cannot provide. When other health systems license your internally developed tool, that becomes powerful third-party endorsement. Marketing messages shift from "we use advanced technology" to "we build technology that other leading institutions trust." The distinction matters significantly in competitive academic medical center markets.

Third, the build-versus-buy decision creates strategic inflection points for vendor partnerships. Health systems developing proprietary tools in one clinical area signal their willingness to bypass traditional vendor relationships when internal development makes strategic sense. For marketers, this means vendor selection becomes part of the institutional brand narrative: which partnerships to maintain, which capabilities to build internally, and how those decisions reflect institutional priorities and capabilities.

The Clinical Complexity Driving Software Decisions

The acceleration of complex therapy approvals makes oncology decision support particularly valuable. FDA approvals in 2026 demonstrate the pace of change: Tudriqev for melanoma and Orzeyful for narcolepsy type 1 both represent novel mechanisms of action requiring new clinical protocols . Tudriqev's combination with nivolumab for patients who progressed on PD-1 blocking therapy creates treatment sequencing decisions that clinicians without decision support must navigate through literature review and consultation—time-consuming processes in a field where treatment delays affect outcomes.

Health systems building proprietary oncology tools can encode their own clinical protocols, integrate real-world outcomes data from their patient populations, and update algorithms as new evidence emerges. This responsiveness becomes increasingly valuable as the time between drug approval and widespread clinical adoption compresses.

For marketing leaders, this clinical complexity creates opportunities to translate technical capabilities into patient-facing messages. Decision support tools that help oncologists match patients to appropriate therapies can be marketed as personalized care, precision medicine, or coordinated treatment planning—messages that resonate with cancer patients researching treatment options and seeking institutions with sophisticated clinical capabilities.

Following the Money: When Build Economics Work

The financial calculus behind proprietary software development deserves scrutiny. Health systems considering this path must account for development costs (typically $2-5 million for complex clinical applications), ongoing maintenance (20-30% of initial development costs annually), regulatory considerations if the tool meets FDA software-as-medical-device criteria, and opportunity costs of deploying technical talent on internal projects rather than revenue-generating clinical work.

Commercialization changes this equation substantially. If a health system can license its tool to even a handful of peer institutions at $200,000-500,000 annually per license, the revenue can offset development costs within three to five years. More importantly, the process of commercialization forces development discipline: tools built for external customers must meet higher standards for documentation, usability, and support than those used only internally.

For healthcare marketers, the commercialization decision creates specific imperatives. Successfully licensing proprietary software to other health systems requires marketing capabilities distinct from patient acquisition or physician recruitment. The target audience shifts to health system CIOs, CMIOs, and oncology service line leaders—audiences requiring different messaging, channels, and credibility markers.

Regulatory and Compliance Considerations

Healthcare marketers promoting proprietary clinical software must navigate FDA oversight of software-as-medical-device (SaMD) and clinical decision support (CDS) tools. The FDA's current framework distinguishes between CDS that provides information to inform clinical decisions (generally lower risk, minimal regulatory burden) and CDS that drives clinical decisions directly (potentially regulated as medical devices requiring premarket review).

Oncology decision support tools occupy a grey zone: they inform treatment selection but typically require clinician confirmation before implementation. Marketing claims about these tools must carefully avoid language suggesting autonomous decision-making or guaranteed outcomes. Acceptable claims focus on workflow efficiency, protocol adherence, and evidence synthesis—measurable operational benefits rather than clinical promises.

Additionally, any marketing of proprietary software to external health systems must address data privacy, interoperability standards, and liability considerations. Marketing materials should clearly communicate whether the software handles PHI, how it integrates with major EHR platforms, and what clinical validation has been completed.

Competitive Positioning in the Build-or-Buy Era

The NYU Langone and Dana-Farber decision creates strategic positioning opportunities—and risks—for competing institutions. Health systems that build proprietary clinical software can claim innovation leadership and technical sophistication. Those that choose vendor partnerships can emphasize different values: collaboration with specialized health tech companies, focus on clinical care rather than software development, or commitment to industry-standard platforms that ensure interoperability.

Neither approach is inherently superior, but the marketing implications differ substantially. Health systems building proprietary tools should emphasize:

• Innovation narrative: Position software development as evidence of clinical leadership and willingness to advance the field
• Recruitment advantage: Highlight access to cutting-edge tools that may not be available at competitor institutions
• Outcome correlation: Connect proprietary technology to measurable improvements in care quality or efficiency
• Commercialization validation: If licensing to other institutions, leverage that as third-party endorsement

Health systems choosing vendor partnerships should counter with:

• Specialization focus: Emphasize that clinical teams focus on patient care while specialized vendors focus on software excellence
• Scale advantages: Highlight that vendor solutions benefit from development investment across hundreds of clients
• Interoperability: Position vendor platforms as more likely to integrate seamlessly across healthcare ecosystems
• Risk mitigation: Note that vendor relationships include ongoing support, updates, and liability considerations

The 1ness Take

The build-versus-buy decision has evolved from a technology question to a strategic marketing question. Health systems that develop proprietary clinical software gain not just operational tools, but positioning assets that create sustained competitive advantage in three distinct ways.

First, proprietary software development forces health systems to articulate their clinical workflows, outcomes data, and institutional knowledge in structured, defensible formats. This process creates intellectual property—algorithms, protocols, and decision logic—that cannot be easily replicated by competitors who purchase vendor solutions. From a marketing perspective, this IP becomes the foundation for thought leadership: published algorithms, conference presentations, and peer-reviewed validation studies that establish institutional expertise.

Second, commercialization transforms a health system from technology consumer to technology producer. This shift enables participation in health tech conferences, vendor exhibitions, and industry partnerships from a position of expertise rather than procurement. The marketing value extends beyond the software itself: media coverage positions institutional leaders as innovators, recruitment materials highlight opportunities to work with cutting-edge technology, and business development teams can approach partners with revenue-generating opportunities rather than only cost proposals.

Third, proprietary clinical software creates structural advantages in value-based care negotiations. Payers increasingly demand demonstrable care coordination capabilities, protocol adherence, and outcomes tracking. Health systems with custom-built decision support tools can show exactly how their technology infrastructure enables these capabilities, with data flows and decision logic transparent and auditable. Competitor institutions using black-box vendor solutions cannot provide the same granular demonstration of capabilities.

Our recommendation for health system marketing leaders: evaluate your institution's current technology narrative. Do your materials emphasize purchased solutions (implying dependence on vendors) or developed capabilities (implying innovation and expertise)? If your institution has built any clinical software internally—even tools used only within your system—consider whether those tools merit external communication as evidence of clinical sophistication. The NYU Langone and Dana-Farber commercialization effort demonstrates that internally developed tools can transition from operational necessities to strategic assets with proper positioning.

For health systems without resources to build proprietary software, the countermove is equally clear: shift messaging from "we use advanced technology" (commodity claim) to "we collaborate with specialized innovators to deliver [specific clinical benefit]" (partnership claim with outcome focus). Vendor partnerships become strategic choices rather than default positions, and marketing materials should explain why specialized software companies deliver advantages that internal development cannot match for your institution's specific priorities.

The Takeaway

The decision to build rather than buy clinical software represents a strategic inflection point with direct marketing implications. Health systems considering this path should:

The NYU Langone and Dana-Farber commercialization effort will not be the last. As FDA approvals accelerate in complex therapeutic areas and health systems compete for high-acuity patients, proprietary clinical software will increasingly become a competitive differentiator. Healthcare marketers must recognize these tools not just as operational infrastructure, but as positioning assets that communicate institutional priorities, capabilities, and innovation leadership.

---